DALI - the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: Procedure and clinical results

European Journal of Clinical Investigation

Volumn 28, Issue 12, 1998, Pages 994-1002

  Drager L J ^a   Julius, U ^b   Kraenzle, K ^c   Schaper, J ^d   Toepfer, M ^e   Zygan, K ^f   Otto, V ^g   Steinhagen Thiessen, E ^d  

^a UNIVERSITY OF APPLIED SCIENCES STRALSUND   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Dialysis Practice   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Dialysis Practice   (Germany)

^f Cardiology Practice   (Germany)

^g FRESENIUS AG   (Germany)

Author keywords

Blood component removal; Chemoadsorption; DALI; Lipid apheresis; Lipoprotein (a); Low density lipoprotein cholesterol

Indexed keywords

ACID CITRATE DEXTROSE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYACRYLAMIDE;

ADSORPTION; ADULT; ANTICOAGULATION; APHERESIS; ARTICLE; BLOOD CELL COUNT; BLOOD VOLUME; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; BLOOD COMPONENT REMOVAL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0032457845     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00395.x     Document Type: Article

References (40)

1. 1 Mann JL, Marr JW. Coronary heart disease prevention trials of diets to contol hyperlipidemia. In: Miller WE, Lewis B, editors. Lipoproteins, Atherosclerosis and Coronary Heart Disease. Amsterdam: Elsevier/North Holland Biomedical Press; 1981. p. 197
2. 2 Frick MH, Elo O, Haapa K, et al. Helsiniki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45
3. 3 Stammler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continues and graded? JAMA 1987;256:2823-8
4. 4 Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74
5. 5 Hombach V, Borberg H, Gadzkowski A, Oette K, Stoffel W. Regression der Koronarsklerose bei familiärer Hypercholesterinämie IIa durch spezifische LDL-Apherese. Dtsch Med Wschr 1986;111:1709-15
6. 6 Thompson GR. Progression and regression of coronary artery disease. Curr Opin Lipidol 1992;3:263-7
7. 7 Pyoeraelae K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994;110/ 2:121-61
8. 8 Study Group European Atherosclerosis Society. Strategies for prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J 1987;8:77-88
9. 9 Havel RJ, Hunninghake DB, Illingworth DR, et al. Lovastatin (Mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study. Ann Intern Med 1987;107:609-15
10. 10 Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern Med 1984;101:598-604
11. 11 Mabuchi H, Sakai T, Sakai Y, et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia: additive effects of compactin and cholestyramine. N Engl J Med 1983;308:609-13
12. 12 Yamamoto A, Yamamura T, Yokoyama S, Sudo H, Matsuzawa Y. Combined drug therapy - cholestyramine and compactin - for familial hypercholesterolemia. Clin Pharmacol 1984;22:493-7
13. 13 Alberts AW. HMG-CoA-reductase inhibitors - the development. Atherosclerosis Rev 1988;18:123-31
14. 14 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
15. 15 Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997;130:191-7
16. 16 Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44
17. 17 Assmann G, Lewis B, Mancini M, Society SGEA. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600
18. 18 Kroon AA, Aengevaeren WR, van der Werf T, et al. Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35
19. 19 Thompson GR, Lowenthal R, Myant B. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1975;1:1208-11
20. 20 Gordon BR, Saal SD. Current status of low density lipoprotein-apheresis for the therapy of servere hyperlipidemia. Curr Opin Lipidol 1996;7:381-4
21. 21 Olbricht CJ. Extrakorporale Elimination von LDL-Cholesterin durch Apherese. Dtsch Med Wschr 1991;116:625-30
22. 22 Lupien PJ, Moojani S, Award JA. New approach to the management of familial hypercholesterolemia: removal of plasma cholesterol based on the principle of affinity chromatography. Lancet 1975;1:1261-5
23. 23 Stoffel W, Borberg H, Greve V. Application of specific extra-corporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet 1981;ii:1005-7
24. 24 von Bayer H, Schwerdtfeger R, Schwartzkopf W, et al. Selective removal of low density lipoproteins (LDL) by plasmapheresis combined with selective plasma-protein ultra-centrifugation (SPU). Plasma Ther Transfus Technol 1983;4:447-58
25. 25 Yamamoto S, Hayashi R, Satatni M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985;5: 613-22
26. 26 Wieland H, Seidel DA. Simple specific method for precipitation of low density lipoprotein. J Lipid Res 1983;24:904-9
27. 27 Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-32
28. 28 Brown MS, Goldstein JLA. Receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47
29. 29 Bosch T. Low-density lipoprotein hemoperfusion using a modified polyacrylate adsorber. In vitro, ex vivo, and first clinical results. Artificial Organs 1996;20:344-5
30. 30 Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artifical Organs 1993;17:640-52
31. 31 Bosch T, Schmidt B, Kleophas W, et al. New procedure for LDL apheresis: First clinical application of an LDL adsorber compatible with human whole blood. Int J Artif Organs 1997;21:977-82
32. 32 Bosch T, Schmidt B, Kleophas W, et al. Clinical efficacy and biocompatibility of the first LDL-adsorber compatible with human whole blood. Int J Artif Organs 1995;18:417
33. 33 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
34. 34 Blagg CR. Acute complications associated with hemodialysis. In: Drukker W, Parson FM, Mahler JF, editors. Replacement of renal function by dialysis, 2nd edn. Boston: Martinus Nijhoff Medical; Division; 1983. p.611-29
35. 35 Sutton DM, Nair RC, Roch G, and the Canadian Apheresis Study Group. Complications of plasma exchange. Transfusion 1989;29:124-7
36. 36 Lupien PJ, Moorjani S, Lou M, Brun D, Gagne C. Removal of cholesterol from blood by affinity binding to heparin-agarose: Evaluation of treatment in homozygous familial hypercholesterolemia. Ped Res 1980;14:113-7
37. 37 Eisenhauer T, Amstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 1987;65:161-8
38. 38 Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions; LDL-apheresis with dextran sulfate, and ACE inhibitors. Lancet 1992;340:908-9
39. 39 Schuff-Werner P, Gohlke H, Bartmann U, et al. and the HELP study group. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32
40. 40 Seidel D, Armstrong VW, Schuff-Werner P. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. 1. Evaluation of Safety and cholesterol-lowering effects during the first 12 month. Eur J Clin Invest 1991;21:375-83.